VIVEbiotech

Executive Summary

VIVEbiotech is a specialized Spanish Contract Development and Manufacturing Organization (CDMO) dedicated exclusively to the development and GMP manufacturing of lentiviral vectors for cell and gene therapies. Founded in 2017 and headquartered in San Sebastián, the company supports over 50 biotech and pharmaceutical clients worldwide, focusing on cancers and rare diseases. With deep virology expertise and adherence to EMA and FDA standards, VIVEbiotech has carved a niche in the rapidly expanding viral vector manufacturing market. The increasing pipeline of ex vivo and in vivo gene therapies, driven by regulatory approvals and technological advancements, positions the company as a key partner for both established firms and emerging biotechs.

Upcoming Catalysts (preview)

• Q3 2026Announcement of capacity expansion at San Sebastián facility70% success
• Q4 2026Client gene therapy receives FDA approval, boosting demand50% success
• Q2 2026Strategic partnership with a top-20 pharma for lentiviral vector supply60% success